Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (750) 750
Publication (82) 82
Book Chapter (26) 26
Book / eBook (16) 16
Book Review (12) 12
Conference Proceeding (4) 4
Dissertation (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (511) 511
index medicus (460) 460
animals (259) 259
female (205) 205
macrocyclic compounds - therapeutic use (185) 185
male (184) 184
antiviral agents - therapeutic use (156) 156
pharmacology & pharmacy (146) 146
drug therapy, combination (130) 130
carbamates - therapeutic use (124) 124
hepatitis c, chronic - drug therapy (119) 119
lactams, macrocyclic - pharmacology (117) 117
benzoquinones - pharmacology (113) 113
hsp90 heat-shock proteins - antagonists & inhibitors (113) 113
mice (113) 113
middle aged (108) 108
anilides - therapeutic use (103) 103
hepacivirus - genetics (103) 103
uracil - analogs & derivatives (100) 100
sulfonamides - therapeutic use (98) 98
macrocyclic compounds - chemistry (97) 97
ritonavir - therapeutic use (90) 90
cancer (89) 89
cell line, tumor (88) 88
chemistry, medicinal (88) 88
hsp90 heat-shock proteins - metabolism (86) 86
biochemistry & molecular biology (85) 85
genotype (85) 85
research (83) 83
heat shock proteins (82) 82
oncology (82) 82
macrocyclic compounds - pharmacology (81) 81
hepatitis c (80) 80
hepatitis c virus (80) 80
health aspects (77) 77
uracil - therapeutic use (76) 76
treatment outcome (75) 75
aged (73) 73
adult (72) 72
ribavirin (72) 72
hepacivirus - drug effects (68) 68
proteins (67) 67
ribavirin - therapeutic use (67) 67
article (66) 66
geldanamycin (66) 66
care and treatment (63) 63
molecular structure (63) 63
antineoplastic agents - pharmacology (61) 61
in-vitro (61) 61
analysis (60) 60
hepatitis c - drug therapy (60) 60
macrocyclic compounds - administration & dosage (60) 60
medicine (60) 60
lactams, macrocyclic (59) 59
apoptosis (58) 58
chemistry, multidisciplinary (58) 58
antineoplastic agents - therapeutic use (57) 57
macrocyclic compounds - adverse effects (57) 57
research article (57) 57
antiviral agents - adverse effects (56) 56
lactams, macrocyclic - therapeutic use (55) 55
benzoquinones (53) 53
macrocyclic compounds (53) 53
ritonavir (53) 53
antiviral agents - administration & dosage (52) 52
multidisciplinary sciences (52) 52
structure-activity relationship (52) 52
drug therapy (50) 50
hsp90 (50) 50
antiviral agents (49) 49
gastroenterology & hepatology (49) 49
inhibitors (49) 49
carbamates - adverse effects (48) 48
science (48) 48
biology (47) 47
drug discovery (46) 46
carbamates - administration & dosage (45) 45
polycyclic compounds (45) 45
therapy (45) 45
drug resistance (44) 44
genetic aspects (44) 44
ligands (44) 44
hcv (43) 43
apoptosis - drug effects (42) 42
microbiology (42) 42
benzoquinones - therapeutic use (41) 41
drug design (41) 41
hepatitis (41) 41
inhibition (41) 41
sofosbuvir (41) 41
anilides - adverse effects (40) 40
cell proliferation - drug effects (40) 40
chemistry (40) 40
neoplasms - drug therapy (39) 39
antineoplastic agents - chemistry (38) 38
interferon (38) 38
dose-response relationship, drug (37) 37
infectious diseases (37) 37
models, molecular (37) 37
rifabutin - analogs & derivatives (37) 37
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (779) 779
Chinese (3) 3
Czech (2) 2
German (2) 2
Hungarian (2) 2
Japanese (2) 2
Spanish (2) 2
French (1) 1
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectives
by Asselah, Tarik and Boyer, Nathalie and Saadoun, David and Martinot‐Peignoux, Michele and Marcellin, Patrick
Liver International, ISSN 1478-3223, 01/2016, Volume 36, Issue S1, pp. 47 - 57
There has been a revolution in the treatment of chronic hepatitis C. Several oral regimens combining direct‐acting antivirals (DAAs) from different families... 
ledipasvir | sofosbuvir | dasabuvir grazoprevir | ombitasvir | velpatasvir | elbasvir | paritaprevir | Ombitasvir | Dasabuvir grazoprevir | Ledipasvir | Paritaprevir | Elbasvir | Velpatasvir | Sofosbuvir | FIBROSIS | ABT-450/R-OMBITASVIR | GENOTYPE 1 | INTERFERON | TREATMENT-NAIVE | DASABUVIR | HCV | GASTROENTEROLOGY & HEPATOLOGY | PROGRESSION | Sofosbuvir - therapeutic use | Anilides - therapeutic use | Benzofurans - therapeutic use | Antiviral Agents - therapeutic use | Humans | Fluorenes - therapeutic use | Hepacivirus - genetics | Uracil - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Sulfonamides - therapeutic use | Female | Imidazoles - therapeutic use | Carbamates - therapeutic use | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Uracil - analogs & derivatives | Virus diseases | Protease inhibitors | Proteases | Interferon | Drug therapy | Hepatitis C virus | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
by Bourlière, Marc and Gordon, Stuart C and Flamm, Steven L and Cooper, Curtis L and Ramji, Alnoor and Tong, Myron and Ravendhran, Natarajan and Vierling, John M and Tran, Tram T and Pianko, Stephen and Bansal, Meena B and de Lédinghen, Victor and Hyland, Robert H and Stamm, Luisa M and Dvory-Sobol, Hadas and Svarovskaia, Evguenia and Zhang, Jie and Huang, K.C and Subramanian, G. Mani and Brainard, Diana M and McHutchison, John G and Verna, Elizabeth C and Buggisch, Peter and Landis, Charles S and Younes, Ziad H and Curry, Michael P and Strasser, Simone I and Schiff, Eugene R and Reddy, K. Rajender and Manns, Michael P and Kowdley, Kris V and Zeuzem, Stefan and POLARIS-1 and POLARIS-4 Investigators and POLARIS-1 and POLARIS-4 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
In two trials involving patients with hepatitis C in whom previous treatment with direct-acting antiviral agents failed, treatment for 12 weeks with... 
GENOTYPE 1 | MEDICINE, GENERAL & INTERNAL | THERAPY | HEPATITIS-C VIRUS | EFFICACY | PROTEASE INHIBITOR GS-9857 | RESISTANCE | DIRECT-ACTING ANTIVIRALS | OPEN-LABEL | COMBINATION | PHASE-2 TRIAL | Hepatitis C - drug therapy | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Hepatitis C - complications | Sofosbuvir - adverse effects | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Care and treatment | Hepatitis C virus | Drug therapy | Patients | Health aspects | Headache | Antiretroviral drugs | Antiviral agents | Proteinase | Clinical trials | Diarrhea | Fatigue | Nausea | Cirrhosis | Hepatitis | Genotypes | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
by Feld, Jordan J and Kowdley, Kris V and Coakley, Eoin and Sigal, Samuel and Nelson, David R and Crawford, Darrell and Weiland, Ola and Aguilar, Humberto and Xiong, Junyuan and Pilot-Matias, Tami and DaSilva-Tillmann, Barbara and Larsen, Lois and Podsadecki, Thomas and Bernstein, Barry
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
by Zeuzem, Stefan and Jacobson, Ira M and Baykal, Tolga and Marinho, Rui T and Poordad, Fred and Bourlière, Marc and Sulkowski, Mark S and Wedemeyer, Heiner and Tam, Edward and Desmond, Paul and Jensen, Donald M and Di Bisceglie, Adrian M and Varunok, Peter and Hassanein, Tarek and Xiong, Junyuan and Pilot-Matias, Tami and DaSilva-Tillmann, Barbara and Larsen, Lois and Podsadecki, Thomas and Bernstein, Barry
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
In this trial in patients with HCV genotype 1 infection and no cirrhosis who had previously been treated with peginterferon and ribavirin, retreatment with... 
SUSTAINED VIROLOGICAL RESPONSE | TREATMENT-NAIVE SUBJECTS | TRIAL | PEGINTERFERON/RIBAVIRIN | MEDICINE, GENERAL & INTERNAL | 3-DAY MONOTHERAPY | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | CHRONIC HEPATITIS-C | GENOTYPE 1 INFECTION | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | RNA, Viral - isolation & purification | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Retreatment | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Ritonavir | Infections | RNA polymerase | Pruritus | Patients | Ribavirin | Cirrhosis | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
by Andreone, Pietro and Colombo, Massimo G and Enejosa, Jeffrey V and Koksal, Iftihar and Ferenci, Peter and Maieron, Andreas and Müllhaupt, Beat and Horsmans, Yves and Weiland, Ola and Reesink, Henk W and Rodrigues, Lino and Hu, Yiran B and Podsadecki, Thomas and Bernstein, Barry
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
by Jacobson, Ira M and Lawitz, Eric and Gane, Edward J and Willems, Bernard E and Ruane, Peter J and Nahass, Ronald G and Borgia, Sergio M and Shafran, Stephen D and Workowski, Kimberly A and Pearlman, Brian and Hyland, Robert H and Stamm, Luisa M and Svarovskaia, Evguenia and Dvory-Sobol, Hadas and Zhu, Yanni and Subramanian, G. Mani and Brainard, Diana M and McHutchison, John G and Bräu, Norbert and Berg, Thomas and Agarwal, Kosh and Bhandari, Bal Raj and Davis, Mitchell and Feld, Jordan J and Dore, Gregory J and Stedman, Catherine A.M and Thompson, Alexander J and Asselah, Tarik and Roberts, Stuart K and Foster, Graham R
Gastroenterology, ISSN 0016-5085, 2017, Volume 153, Issue 1, pp. 113 - 122
Background & Aims Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment... 
Gastroenterology and Hepatology | Direct-Acting Antiviral Agent | Shortened Duration Therapy | Clinical Trial | Comparison | PROTEASE INHIBITOR GS-9857 | SIMEPREVIR PLUS SOFOSBUVIR | COMBINATION | CHALLENGES | GENOTYPE 1 | TREATMENT-NAIVE | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | DIRECT-ACTING ANTIVIRALS | GASTROENTEROLOGY & HEPATOLOGY | Humans | Middle Aged | Male | Carbamates - administration & dosage | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Drug Therapy, Combination | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Macrocyclic Compounds - therapeutic use | Sofosbuvir - administration & dosage | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Sulfonamides - administration & dosage | Medical colleges | Care and treatment | Protease inhibitors | Proteases | Transplantation of organs, tissues, etc | Product development | Hepatitis C virus | Hepatitis C | Health aspects | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
by Kwo, Paul Y and Mantry, Parvez S and Coakley, Eoin and Te, Helen S and Vargas, Hugo E and Brown, Robert and Gordon, Fredric and Levitsky, Josh and Terrault, Norah A and Burton, James R and Xie, Wangang and Setze, Carolyn and Badri, Prajakta and Pilot-Matias, Tami and Vilchez, Regis A and Forns, Xavier
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 25, pp. 2375 - 2382
In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | MULTICENTER | VIRUS-INFECTION | TELAPREVIR | THERAPY | DASABUVIR | HEPATITIS-C RECURRENCE | GRAFT | RIBAVIRIN | PEGINTERFERON-ALPHA-2B | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Calcineurin Inhibitors - blood | Young Adult | Ribavirin - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Calcineurin Inhibitors - therapeutic use | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Uracil - analogs & derivatives | Care and treatment | Usage | Ritonavir | Liver | Dosage and administration | Transplantation | Hepatitis C | Ribavirin | Headache | Transplants & implants | Erythropoietin | Syngeneic grafts | Calcineurin | Calcineurin inhibitors | Blood transfusion | Immunosuppressive agents | Hepatitis | Allografts | Drug therapy | Genotypes | Antiviral agents | Recurrent infection | Fatigue | Proteinase inhibitors | Patients | RNA-directed RNA polymerase | Cough | Blood levels | Graft rejection | Fibrosis | Interferon | Antiviral drugs | Liver transplantation | Index Medicus | Abridged Index Medicus | Medicaments antivírics | Hepatitis C virus | Virus de l'hepatitis C | Trasplantament hepàtic | Hepatic transplantation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
by Poordad, Fred and Hezode, Christophe and Trinh, Roger and Kowdley, Kris V and Zeuzem, Stefan and Agarwal, Kosh and Shiffman, Mitchell L and Wedemeyer, Heiner and Berg, Thomas and Yoshida, Eric M and Forns, Xavier and Lovell, Sandra S and Da Silva-Tillmann, Barbara and Collins, Christine A and Campbell, Andrew L and Podsadecki, Thomas and Bernstein, Barry
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1973 - 1982
In patients with HCV genotype 1 infection and cirrhosis, the rate of sustained virologic response was 92% with three new antiviral agents plus ribavirin for 12... 
SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | UNITED-STATES | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | TELAPREVIR | THERAPY | GENOTYPE 1 INFECTION | BOCEPREVIR | HCV INFECTION | EPIDEMIOLOGY | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Logistic Models | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Complications and side effects | Evaluation | Care and treatment | Usage | Hepatitis C | Liver cirrhosis | Ribavirin | Headache | Antiviral agents | Ritonavir | Body weight | Fatigue | Infections | Nausea | Proteinase inhibitors | RNA polymerase | Patients | Cirrhosis | Liver cancer | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Cirrosi hepàtica | Inhibidors enzimàtics | Enzyme inhibitors | Hepatic cirrhosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
by Ferenci, Peter and Bernstein, David and Lalezari, Jacob and Cohen, Daniel and Luo, Yan and Cooper, Curtis and Tam, Edward and Marinho, Rui T and Tsai, Naoky and Nyberg, Anders and Box, Terry D and Younes, Ziad and Enayati, Pedram and Green, Sinikka and Baruch, Yaacov and Bhandari, Bal Raj and Caruntu, Florin Alexandru and Sepe, Thomas and Chulanov, Vladimir and Janczewska, Ewa and Rizzardini, Giuliano and Gervain, Judit and Planas, Ramon and Moreno, Christophe and Hassanein, Tarek and Xie, Wangang and King, Martin and Podsadecki, Thomas and Reddy, K. Rajender and PEARL-IV Study and PEARL-III Study
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1983 - 1992
Among previously untreated patients with HCV genotype 1 infection, three new antiviral agents, with or without ribavirin, resulted in high rates of sustained... 
ANTIVIRAL AGENTS | MEDICINE, GENERAL & INTERNAL | INTERFERON | TREATMENT-NAIVE | TELAPREVIR | SOFOSBUVIR | 1 HEPATITIS-C | BOCEPREVIR | DACLATASVIR | COMBINATION | PEGINTERFERON | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Hemoglobins - analysis | Evaluation | Usage | Care and treatment | Safety and security measures | Clinical trials | Hepatitis C | Ribavirin | Headache | Ritonavir | Body weight | Fatigue | Infections | Nausea | Ribonucleic acid--RNA | Patients | Cirrhosis | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
by Kowdley, Kris V and Lawitz, Eric and Poordad, Fred and Cohen, Daniel E and Nelson, David R and Zeuzem, Stefan and Everson, Gregory T and Kwo, Paul and Foster, Graham R and Sulkowski, Mark S and Xie, Wangang and Pilot-Matias, Tami and Liossis, George and Larsen, Lois and Khatri, Amit and Podsadecki, Thomas and Bernstein, Barry
The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 3, pp. 222 - 232
In this phase 2 study, peginterferon-free regimens were effective in patients with hepatitis C virus genotype 1 infection. Chronic hepatitis C virus (HCV)... 
MEDICINE, GENERAL & INTERNAL | PLUS RIBAVIRIN | TELAPREVIR | BOCEPREVIR | INHIBITOR | HCV INFECTION | ASSOCIATION | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | Young Adult | Adult | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Hepacivirus - isolation & purification | Administration, Oral | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | RNA, Viral - analysis | Genotype | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Antiviral agents | Care and treatment | Dosage and administration | Research | Hepatitis C | Headache | Ritonavir | Body weight | Fatigue | Nausea | Proteinase inhibitors | Patients | Ribavirin | Cirrhosis | Sleep disorders | Genotype & phenotype | Hepatitis | Interferon | Drug therapy | Drug dosages | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights